Mechanisms of harmol sulfate biliary excretion in mice and rats

Previous experiments demonstrated that the biliary excretion of harmol sulfate (HS) was mediated by Bcrp, and not by Mrp2 or P-glycoprotein in mice. However, recent reports suggested that species differences in hepatic canalicular transport mechanisms for a given substrate exist between mice and rats. In the present study, biliary excretion of HS was examined in perfused livers from mice and rats in the absence or presence of the P-glycoprotein and Bcrp inhibitor, GF120918. As expected, in mouse liver perfusions the biliary excretion of HS was decreased ~3.5-fold by GF120918, consistent with previous reports of Bcrp-mediated HS biliary excretion. However, despite sufficient hepatic unbound concentrations of GF120918 to achieve extensive inhibition of Bcrp, the biliary excretion of HS was not decreased significantly in rats (50 ± 12 vs. 41 ± 6 %). In summary, biliary excretion of HS was mediated by a GF120918-sensitive mechanism in mice, previously elucidated as Bcrp. In contrast the pathway responsible for HS biliary excretion in rats was not impaired by GF120918. Thus, transport mechanism(s) responsible for harmol sulfate biliary excretion appear to differ between mice and rats. 0% B, 4.1–6.0 min linear gradient to 0% B, 3.1–4 min hold at 0% B; flow rate = 0.65 mL/min; 1–5 min directed to mass spectrometer) and were detected in positive ion mode using multiple reaction monitoring: harmol: 199 → 131 m/z, HS: 279 → 199 m/z, cimetidine: 253 → 117 m/z. Analytes in mouse samples were eluted from an Aquasil C18 column (2.1 × 50 mm, d p = 5 µm, Thermo Electron Corporation, Waltham, MA) using a mobile phase gradient (A: 0.05% formic acid, B: 0.05% formic acid in methanol; 0–0.75 min hold at 0% B, 0.75–2 min linear gradient to 70% B, 2–3.5 min hold at 70% B, 3.5–3.6 min linear gradient to 0% B, 3.6–4 min hold at 0% B; flow rate = 0.75 mL/min; 0.8–4 min directed to mass spectrometer) and were detected in positive ion mode: harmol: 199 → 131 m/z, cimetidine: 253 → 117 m/z, or negative ion mode: HS: 277 → 197 m/z, cimetidine: 251 → 157 m/z.

[1]  Kim L R Brouwer,et al.  The Important Role of Bcrp (Abcg2) in the Biliary Excretion of Sulfate and Glucuronide Metabolites of Acetaminophen, 4-Methylumbelliferone, and Harmol in Mice , 2006, Molecular Pharmacology.

[2]  Kim L. R. Brouwer,et al.  Differential Involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in Biliary Excretion of 4-Methylumbelliferyl Glucuronide and Sulfate in the Rat , 2006, Journal of Pharmacology and Experimental Therapeutics.

[3]  Kim L R Brouwer,et al.  Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[4]  A. Dahan,et al.  Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[5]  K. Brouwer,et al.  Hepatobiliary Disposition of the Metabolically Stable Opioid Peptide [d-Pen2, d-Pen5]-Enkephalin (DPDPE): Pharmacokinetic Consequences of the Interplay between Multiple Transport Systems , 2004, Journal of Pharmacology and Experimental Therapeutics.

[6]  Yuichi Sugiyama,et al.  ABCG2 Transports Sulfated Conjugates of Steroids and Xenobiotics* , 2003, Journal of Biological Chemistry.

[7]  M. Vore,et al.  The effect of troglitazone biliary excretion on metabolite distribution and cholestasis in transporter-deficient rats. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[8]  C. Funk,et al.  Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. , 2001, Molecular pharmacology.

[9]  T. Litman,et al.  Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. , 1999, Cancer letters.

[10]  C. Goresky,et al.  Transport, binding, and metabolism of sulfate conjugates in the liver. , 1994, Chemico-biological interactions.

[11]  G. Mulder,et al.  Secretion of the organic anion harmol sulfate from liver into blood. Evidence for a carrier-mediated mechanism. , 1985, Biochemical pharmacology.

[12]  K. Pang,et al.  Retrograde perfusion to probe the heterogeneous distribution of hepatic drug metabolizing enzymes in rats. , 1981, The Journal of pharmacology and experimental therapeutics.

[13]  G. Mulder,et al.  UDP glucuronyltransferase and phenolsulfotransferase from rat liver in vivo and in vitro--IV. Species differences in harmol conjugation and elimination in bile and urine in vivo. , 1975, Biochemical pharmacology.

[14]  C. Klaassen,et al.  Species variation in toxication and detoxication of acetaminophen in vivo: a comparative study of biliary and urinary excretion of acetaminophen metabolites. , 1988, The Journal of pharmacology and experimental therapeutics.